Formycon (FYB) Company presentation summary

Company overview and strategy

• Established in 2012 in Munich, focused exclusively on biosimilars with a business model based on success share and royalty streams.

• Employs 200 people from over 27 countries, with more than 80% in R&D.

• Pipeline includes three launched biosimilars and four candidates in development.

• Mission centers on improving patient access and easing healthcare financial strains.

Market opportunity and growth drivers

• 39 blockbuster drugs with over $190 billion in sales will lose exclusivity by 2032, creating major biosimilar opportunities.

• Biosimilars are the fastest-growing pharma segment, with US CAGR of 97% from 2015–2021.

• Strategic levers for growth include geographic diversification, smart portfolio, excellence and innovation, and lean development.

Product portfolio and milestones

• Commercialized biosimilars: FYB201 (Lucentis®), FYB202 (Stelara®), FYB203 (Eylea®); four additional candidates in development.

• FYB201 launched in 24 countries; FYB202 launched in US, Europe, and Canada; FYB203 launched in EU, US launch planned for Q4 2026.

• FYB206 (Keytruda® biosimilar) completed clinical development, partnerships in MENA, US, Canada, and APAC; launch expected after 2029.

• FYB208 (Dupixent® biosimilar) achieved technical proof of similarity, with partnering activities starting in 2026.